Genmab Surges 11% on Rina-s Data, Bank Target Price Hikes

Genmab shares jumped 11% after presenting study data for drug candidate rina-s, prompting multiple major banks to raise target prices. The move reflects positive market reaction to clinical results, though the durability and regulatory path of the data remain unverified. This is a company-specific catalyst with limited macro impact.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works